Over the last few years, major pharmaceutical and biotechnology companies are associating their therapeutic drugs with diagnostic assays to monitor the drug response. This, in turn, enables the pharma companies to facilitate specific drugs for patients with cancer, genetic, and infectious diseases. Cell-free DNA isolation and extraction is one such recently developed method and is gaining immense popularity in the healthcare sector, rapidly. According to the latest market intelligence report by BIS Research titled, ‘Global Cell-Free DNA Isolation and Extraction Market-Analysis and Forecasts (2018-2026),’ the market is anticipated to grow over $442.8 million by the year 2026. This significant market growth is owing to the rising demands for prenatal testing among high-risk pregnant women and increase in demands for liquid biopsy.
Cell-Free DNA (cfDNA) testing is a new and efficient technology in which the free-flowing DNA fragments from a liquid sample such as blood or saliva of the patient are analyzed to screen a disease. The cell-free DNA is found in blood, plasma, serum, or other body fluids, and hold a clinical significance in diagnosis, monitoring, and detection of various non-invasive diseases. The advent of various screening procedures such as NIPT and liquid biopsy are the prominent factors for the growth of the cfDNA isolation and extraction market along with improved efficiency of screening results. These advanced testing procedures enable the companies in the medical diagnostic industry to remain competitive as well as to manage their profits, significantly.
The cell-free DNA isolation and extraction market is driven by various factors such as the inclusion of cancer screening tests in national screening programs, increasing discretionary funding for cancer research, associating drugs with diagnostic assays, and exploring next-generation sequencing techniques for cancer diagnostics. Government and regulatory bodies in developed countries are putting in substantial efforts to support companies in developing effective diagnostic tests. Lack of standardization and appropriate controls of cell-free DNA kits, insurance coverage, reimbursement issues, and enormous R&D investments with no therapeutic results are some of the restraining factors for the growth of cfDNA isolation and extraction market.
The global market for cell-free DNA isolation and extraction can be segmented by product, platform, applications, and region types. Among the products, the extraction kits segment holds the highest share of the total cfDNA extraction and isolation market and is anticipated to register a significant growth rate in future. The magnetic bead-based kits enable all the processes to be conducted at room temperature, thus, replacing traditional proteinase and heat treatment methods. As compared to conventional cfDNA methods, there is also a significant reduction in processing time. Geographically, Asia-Pacific is expected to register a CAGR of 21.5% in terms of volume, during the forecast period.
BIS Research has conducted extensive research on the global cell-free DNA isolation and extraction market and compiled the observation and insight in this report. The market intelligence report aims at providing an in-depth analysis of the key development strategies, marketing strategies and market trend dynamics which include drivers, restraints, and opportunities prevailing in the industry.
For further queries, please write to us at [email protected] or call us at: +1 650 228 0182.